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OBJECTIVES This study sought to identify determinants of the exercise rise in plasma levels of cardiac
natriuretic peptides (NPs) in patients with coronary artery disease (CAD).
BACKGROUND During stress, there is a variable rise in the plasma level of NPs, but this rise frequently reaches
levels that are known to lower the cardiac load and that thus might be beneficial to CAD
patients.
METHODS Plasma venous concentrations of atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) were determined at rest and peak exercise in 104 patients with chronic CAD
who were referred to exercise thallium-201 (201Tl) single-photon emission computed
tomography (SPECT) and radionuclide angiography.
RESULTS The extent of scarred myocardium by 201Tl-SPECT and patient age were the best
independent predictors of NP concentrations at rest, but also of increases in NP concentration
during exercise (all p  0.001). Moreover, beta-blocking treatment was an additional and
strong independent predictor of the increase in NP concentrations at exercise (p  0.001 for
ANP; p  0.001 for BNP). On average, exercise increases in NP concentrations were more
than twice as high in patients with (n  55) than in those without (n  49) beta-blocker
treatment (ANP:49 63 vs.22 25 ng/l, p 0.01; BNP:24 5 vs.11 15 ng/l,
p  0.04), whereas NP concentrations at rest were equivalent in the two groups (ANP: 34 
34 vs. 30  33 ng/l, p  NS; BNP: 85  152 vs. 57  101 ng/l, p  NS).
CONCLUSIONS Patients with chronic CAD exhibit much higher exercise releases of ANP and BNP when
they are treated with beta-blockers. This enhanced secretion of potent vasodilating and
natriuretic agents constitutes an original therapeutic mechanism for further protecting
diseased hearts against stress. (J Am Coll Cardiol 2004;43:353–9) © 2004 by the American

















desting plasma concentrations of atrial and brain natriuretic
eptide (ANP and BNP, respectively) are enhanced at
ong-term in a number of cardiac diseases in which these
wo peptides exert beneficial effects through promotion of
asodilation and natriuresis, as well as inhibition of the
enin-angiotensin aldosterone and sympathetic nervous sys-
ems (1,2). In addition, during stress, a prompt release from
ardiac stores leads to an abrupt rise in plasma levels of BNP
nd especially of ANP (1,2). However, this rise is highly
ariable (3–6), although it is generally high for both
eptides in patients with heart failure and much more
imited in normal subjects (5), in whom a clearly significant
ise was documented at exercise for the plasma level of ANP
ut not BNP (3). Nevertheless, when high levels of cardiac
atriuretic peptides (NPs) are released at exercise, their
rompt vasodilator and diuretic effects may be expected to
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Manuscript received March 25, 2003; revised manuscript received July 2, 2003,accepted July 7, 2003.ower cardiac load (7–9) and thus beneficial to patients with
oronary artery disease (CAD). Up to now, however, the
agnitude of this exercise release of NPs has only been
oorly analyzed in CAD patients. Therefore, this study was
imed at identifying the main determinants of the exercise
ise in plasma concentrations of NPs in patients with
hronic CAD.
ETHODS
tudy population. We prospectively and consecutively in-
luded all patients: 1) who had a proven history of CAD; 2)
ho had been referred to our department for the perfor-
ance of both exercise thallium-201 (201Tl) single-photon
mission computed tomography (SPECT) and rest equilib-
ium radionuclide angiography (RNA); and 3) who gave
nformed consent to participate. Diagnosis of CAD was
ased on the presence of one or more significant (50%)
oronary narrowings on a previous angiogram.
The exclusion criteria were congenital or valvular heart
isease, hypertrophic or idiopathic dilated cardiomyopathy,
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Cardiac NPs and Beta-Blockers February 4, 2004:353–9he natriuretic peptide system (renal insufficiency and un-
ontrolled systemic hypertension).
adionuclide investigations. The way to perform and
nalyze exercise 201Tl-SPECT images has already been
escribed in detail elsewhere (10,11). Briefly, an exercise test
as performed in the upright position on a bicycle ergome-
er; the protocol was started at 20 W and increased by 20 W
very 2 min. Exercise end points were physical exhaustion,
ngina pectoris, 2-mm ST-segment depression, sustained
entricular tachyarrhythmia, 10 mm Hg fall in systolic
ressure, or achievement of the maximal predicted heart rate
HR) (220  age). At peak exercise, 37 MBq 201Tl per 25
g body weight was injected intravenously, and 201Tl
ctivity, corresponding to one-third of that given at exercise,
as injected 10 min before rest imaging. Reconstructed
lices were scored visually by a blinded observer using both
20-segment division of the left ventricle (LV) and a
-point grading system.
The extent of predominantly scarred myocardium (non-
iable myocardium) was determined as the percentage of
V segments showing fixed defects with 50% uptake at
est re-injection, and the extent of ischemic and viable
yocardium was determined as the percentage of LV
egments showing either reversible or fixed defects with
50% uptake at rest re-injection (10,11).
Multigated equilibrium RNA was performed at rest in
he supine position, just after the end of 201Tl acquisitions.
s previously described (12), 740 to 1,110 MBq technetium-
9m (99mTc)-pertechnetate was injected intravenously, and
he camera head was set to maximize ventricular separation
n the left anterior oblique orientation. Repetitive sampling
f cardiac cycle, subdivided into 16 frames, was acquired
ntil a minimum of 300,000 counts/frame was obtained.
he LV ejection fraction (LVEF) was calculated using a
onventional count-based method; end-systolic, end-
iastolic, and background-count regions of interest were
rawn manually (12).
lood sampling and biochemical measurements. For
ach patient, three venous blood samples of 5 ml were
rawn in the seated position from a catheter inserted into
he antecubital vein: 1) immediately before starting the
xercise test, patients having previously observed an at least
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CAD  coronary artery disease
HR  heart rate
LV  left ventricular
LVEF  left ventricular ejection fraction
NP  natriuretic peptide
RNA  radionuclide angiography
SPECT  single-photon emission computed tomography
201Tl  thallium-2010 min rest; 2) at the maximal work load of bicycle exercise; 6nd 3) at the end of the exercise SPECT acquisition,
orresponding to a time interval of 20 min from the end of
xercise. These samples were collected in polystyrene tubes
ontaining EDTA and aprotinin (500 kallikrein inactivator
/ml); they were placed on ice and then centrifuged at
,000 g; and plasma was stored at 70°C.
The ANP and BNP concentrations were determined
sing commercially available kits (Shionoria, Shionogi,
saka, Japan) (13) using two monoclonal antibodies bind-
ng either human ANP or human BNP. Minimal detectable
oncentrations are 5 pg/ml for ANP and 2 pg/ml for BNP,
nd the inter- and intra-assay coefficient of variations is
6% for both ANP and BNP.
tatistical analysis. Continuous variables are expressed as
he mean value  SD; they were compared using nonpara-
etric tests. The Wilcoxon rank-sum test was used for
aired series, and the Mann-Whitney U test was used for
wo-group unpaired comparisons. Discrete variables are
xpressed as percentages; they were compared using the
hi-square or Fisher exact test when the smallest expected
requency was 5. A p value 0.05 was considered to
ndicate a significant difference. Multivariate analyses were
erformed stepwise using ascending linear regression anal-
ses (SPSS version 10.0). At each step, the limit for
ignificance to enter a variable was 0.05, and the limit to
emove a variable was 0.10.
ESULTS
haracteristics of study patients. The main characteristics
f patients are listed in Table 1. A recent history of chest
ain was documented in 48 patients (46%), among whom
4 had typical angina. The remainder had been referred to
xercise SPECT for viability assessment (18%) or assess-
ent of the evolution of CAD in the absence of any sign or
ymptom of ischemia (36%).
Daily-life medical treatment included beta-blockers in 78
atients, among whom 23 had stopped these medications to
nhance the sensitivity of exercise SPECT (2 days before).
linical data and results of radionuclide investigations were
ot significantly different between these 23 patients and the
thers. Therefore, only 55 patients underwent the tests
hile on their beta-blocking medications: 26 had atenolol,
0 had metoprolol, 6 had celiprolol, 6 had acebutolol, 4 had
isoprolol, 1 had sotalol, 1 had propanolol, and 1 had
arvedilol. At exercise, compared with the 49 patients not
reated with beta-blockers, the 55 who received beta-
lockers had lower values (mean  SD) of maximal HR
116 19 vs. 141 19 beats/min, p 0.001), HR increase
difference between maximal and resting values: 46  17
s. 58  17 beats/min, p  0.001), maximal systolic
ressure (171  30 vs. 186  28 mm Hg, p  0.003), and
ystolic pressure increase (difference between maximal and
esting values (49  21 vs. 58  20 mm Hg, p  0.04).
At 201Tl-SPECT, an ischemic area was documented in
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February 4, 2004:353–9 Cardiac NPs and Beta-Blockersound in 47 (45%). The rest radionuclide LVEF was
bnormal (0.50) in 41 patients (39%).
volution of NP concentrations at exercise. At rest, the
lasma concentration of ANP was lower than that of BNP
32  34 vs. 72  131 ng/l, p  0.001). However, the
able 1. Main Characteristics of the Study Patients
linical data
Age (yrs) 59  11
Male gender 98 (94%)
Diabetes mellitus 15 (14%)
Hypertension 26 (25%)
Q-wave on ECG 73 (70%)
History of infarction 83 (80%)
Chest pain 48 (46%)
Typical angina 34 (33%)
Dyspnea (NYHA class  II) 22 (21%)
ain medications
Beta-blockers 55 (53%)
Calcium antagonists 15 (14%)
Nitrates or molsidomin 29 (28%)
Enzyme-converting inhibitors 46 (44%)
Diuretics 16 (15%)
xercise testing
Maximal work load (W) 126  33
Maximal heart rate (beats/min) 128  22
Increase in heart rate (beats/min) 51  18
Maximal systolic pressure (mm Hg) 178  31
Increase in systolic pressure (mm Hg) 54  25
Maximal rate–pressure product (100) 231  68
Increase in rate–pressure product (100) 136  56
1-mm ST-segment depression 22 (21%)
Angina or ST-segment depression 24 (23%)
01Tl-SPECT abnormalities (%LV)
Extent of scarred area 10  13
Extent of ischemic area 12  10
est radionuclide LVEF 0.51  0.14
ata are presented as the mean value  SD or number (%) of patients.
ECG  electrocardiogram; LVEF  left ventricular ejection fraction; NYHA 
ew York Heart Association; 201Tl-SPECT  thallium-201 single-photon emission
omputed tomography.
able 2. P Values for Univariate Predictors (p  0.1 on Univaria




Age 0.001 0.003 0.088
History of infarction 0.001 0.003 NS
Dyspnea  0.001  0.001 0.003
Beta-blockers NS 0.011 0.007
Enzyme-converting inhibitors 0.040 0.013 0.070
Diuretics 0.006 0.006 0.021
xercise 201Tl-SPECT
Maximal work load  0.001 0.009 NS
Maximal heart rate 0.022 0.060 NS
Increase in heart rate 0.058 NS 0.065
Maximal systolic pressure 0.098 NS NS
Increase in systolic pressure 0.003 0.009 NS
Maximal rate–pressure product 0.037 NS NS
Increase in rate–pressure product 0.015 NS 0.092
SPECT extent of scarred area  0.001  0.001  0.001
est radionuclide LVEF  0.001  0.001 0.002NP and BNP  atrial and brain natriuretic peptide, respectively; NS  nonsignificant; oncrease in plasma concentrations during exercise was higher
or ANP than for BNP (difference between peak exercise
nd rest concentrations: 36  51 vs. 18  32 ng/l, p 
.001), and the subsequent decrease after exercise was also
igher for ANP than for BNP (difference between 20-min
ecovery and peak exercise concentrations: 19  44 vs.
11  32 ng/l, p  0.005). The total concentration of
eptides, expressing a plasma concentration of both pep-
ides as an overall, exhibited a 74  77% increase during
xercise.
orrelates of resting plasma concentrations of NPs.
nivariate predictors of NP concentrations at rest
extracted from the parameters listed in Table 1) are
isplayed in Table 2. High NP concentrations at rest were
ssociated with aging and variables reflecting: 1) the pres-
nce and severity of necrosis (history of infarction, extent of
carred area on 201Tl-SPECT); 2) the severity of LV
ysfunction (LVEF); 3) symptoms and treatments of car-
iac insufficiency (New York Heart Association functional
lass II dyspnea, diuretics, and enzyme-converting inhib-
tors); and 4) weaker adaptation at exercise (maximal work
oad, maximal HR, and increase in blood pressure).
In contrast, rest concentrations were not significantly
ifferent between patients with and those without beta-
locker treatment for both ANP (34  35 vs. 30  33 ng/l,
 NS) and BNP concentrations (85  152 vs. 57  101
g/l, p  NS) and for the total concentration of NPs
120  177 vs. 87  130 ng/l, p  NS).
By multivariate analysis, the sole best independent pre-
ictors of the total rest concentration of NPs were: 1) the
xtent of scarred myocardium on 201Tl-SPECT (p 
.001); and 2) patient age (p  0.001). As detailed in Table
, similar results were obtained when rest concentrations of
NP and BNP were considered separately. Figure 1 illus-
rates the strong correlation between the plasma venous
nalysis) of the Rest and Exercise Plasma Concentrations and of
etic Peptides
ANP BNP
Rest Exercise Increase Rest Exercise Increase
0.001 0.008 NS 0.003 0.004 0.048
0.032 0.08 NS  0.001  0.001 0.060
0.001 0.001 0.025 0.001  0.001 0.001
NS 0.012 0.010 NS 0.052 0.043
0.027 0.015 0.099 0.048 0.033 0.023
0.001 0.005 0.035 0.046 0.048 NS
0.001 NS NS 0.001 0.003 NS
0.014 NS NS 0.032 0.052 NS
NS NS 0.018 0.056 NS NS
NS NS NS 0.086 NS NS
0.008 0.07 NS 0.003 0.006 NS
0.062 NS NS 0.041 0.087 NS
0.044 NS 0.069 0.016 0.044 NS
0.001 0.001 0.024  0.001  0.001  0.001
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Cardiac NPs and Beta-Blockers February 4, 2004:353–9oncentrations of NPs, determined at rest, and the com-
ined information provided by aging and the extent of
carred myocardium.
orrelates of exercise increase in plasma concentrations
f NPs. The exercise increase in plasma concentration of
Ps, determined by the difference between peak exercise
nd rest values, was strongly dependent on the rest concen-
ration of NPs (p  0.001). Other univariate predictors are
isplayed in Table 2.
A higher exercise increase in NP concentration was
ignificantly related to variables previously identified as
redictors of a higher NP concentration at rest: SPECT
xtent of scarred area, LVEF, dyspnea, and diuretic treat-
ent. In contrast, beta-blocking treatment was a predictor
f exercise increase in NP concentration, although it was not
predictor of NP concentration at rest. On average, the
xercise increase in peptide concentration was more than
able 3. Multivariate Analysis: Best Independent Predictors of th
ANP  BNP A
ll variables included All variables included
Extent of scarred area (p  0.001) Extent of scarred ar
Age (p  0.001) Age (p  0.001)
xclusion of extent of scarred area Exclusion of extent of
LVEF (p  0.001) Maximal work load
Age (p  0.001) Dyspnea (p  0.01
Enzyme-converting
xclusion of age Exclusion of age
Extent of scarred area (p  0.001) Maximal work load
Maximal work load at exercise (p  0.001) Extent of scarred ar
bbreviations as in Tables 1 and 2.
igure 1. Total plasma venous concentrations of natriuretic peptides
etermined at rest for patients stratified into three groups as a function of
he extent of predominantly scarred left ventricular (LV) myocardium on
hallium-201 single-photon emission computed tomography (0%, 1%–
9%, and 20%) and into two subgroups according to age: 65 years
white bars) and65 years (black bars). The hatched portion of each bar
epresents the part related to the atrial natriuretic peptide concentration
nd the open portion to brain natriuretic peptide.wice as high in patients with than in those without
eta-blocker treatment for both ANP (49 60 vs.22
5 ng/l, p  0.01) and BNP (24  40 vs. 11  15 ng/l,
 0.04).
By multivariate analysis, the best independent predictors
f the exercise increase in the total concentration of NPs
ere: 1) rest concentration of NPs (p  0.001); 2) exercise
ncrease in HR (p 0.001); and 3) beta-blocking treatment
p  0.001). The same parameters were selected when
ultivariate analysis was applied to predict the plasma level
f NPs that was reached at peak exercise. In addition, as
etailed in Table 4, similar results were obtained in the
ultivariate prediction of exercise increase of ANP only.
owever, predictors of exercise increase in BNP only were
lightly different: the rest concentration of BNP was selected
n place of total rest concentration of NPs, and exercise
ncrease in rate–pressure product was selected in place of
xercise increase in HR; LVEF became an additional
redictor.
Moreover, when beta-blocking treatment was initially
xcluded from the multivariate analyses, it could always be
ubsequently included within the selected models (p 
.001 for prediction of exercise increase in NP concentra-
ion, p  0.001 for that of ANP, and p  0.04 for that of
NP).
Figure 2 illustrates the specific impact of beta-blockers on
he exercise increase in NP concentrations. This figure
hows the evolutions of NP concentrations at exercise,
ccording to the presence or absence of either beta-blocking
reatment or scarred area on SPECT. Although both
ariables were associated with higher levels of NPs at peak
xercise, only the scarred area was additionally associated
ith higher levels of NPs at rest. Patients treated with
eta-blockers had the particularity of exhibiting more
brupt changes: higher exercise increase and higher post-
xercise decrease in NP concentrations.
Figure 3 illustrates the additional predictive information
rovided by exercise increase in HR and beta-blocking
reatment. Patients were separated into two groups accord-
ng to the mean value of increase in HR at exercise (51
eats/min). The exercise increase in NP concentration was
onsistently higher in patients with than in those without
sting Plasma Concentration of Natriuretic Peptides
BNP
All variables included
 0.001) Extent of scarred area (p  0.001)
Age (p  0.001)
ed area Exclusion of extent of scarred area
ercise (p  0.001) LVEF (p  0.001)
Age (p  0.002)
itors (p  0.029)
Exclusion of age
ercise (p  0.001) Extent of scarred area (p  0.001)
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February 4, 2004:353–9 Cardiac NPs and Beta-Blockers51 beats/min, but this relationship was shifted to higher
P levels in patients on beta-blockers.
On average, the difference in exercise increase in NPs,
hich was documented between patients with and those
ithout beta-blockers, was as much as 40 ng/l in the overall
opulation. However, similar to what was observed for the
xercise increase in NPs, this difference was markedly
ependent on the rest level of NPs; for instance, it was only
3 ng/l in the half of population with the lowest levels of
Ps at rest (52 ng/l).
ISCUSSION
n a general population of patients with chronic CAD, the
resent study confirms previous reports where exercise was
hown to induce a prompt rise in the venous concentrations
f NPs (1–6), but we also found that this rise was markedly
nhanced in patients on beta-blockers.
During exercise, a release of NPs from secretory granules
s likely to allow a prompt rise in the blood levels of NPs.
hese granules are mainly located within atrial myocytes,
lthough they also develop within ventricular myocytes in
atients with heart failure (14–18), and they contain higher
mounts of ANP than BNP (15,16). This last point explains
ur observation that the exercise rise in the plasma concen-
ration of ANP was twofold higher than that of BNP, on
verage.
nfluence of resting plasma levels of NPs. The amount of
Ps stored within the secretory granules is known to rise in
arallel to the resting blood concentrations of NPs (15–18).
hat is why the exercise increase in NP concentration was
trongly correlated to the rest concentration of NPs. Indeed,
able 4. Multivariate Analysis: Best Independent Predictors of th
atriuretic Peptides
ANP  BNP
ll variables included All variables included
Rest level of both peptides (p  0.001) Rest level of both p
Increase in heart rate (p  0.001) Increase in heart ra
Beta-blockers (p  0.001) Beta-blockers (p 
xclusion of peptide dosages Exclusion of peptide
Extent of scarred area (p  0.001) Increase in heart ra
Increase in heart rate (p  0.001) Beta-blockers (p 
Beta-blockers (p  0.001) LVEF (p  0.038)
Age (p  0.025) Diuretics (p  0.04
xclusion of increase in heart rate Exclusion of increase
Rest level of both peptides (p  0.001) Rest level of both p
Increase in rate–pressure product (p  0.001) Increase in rate–pre
Beta-blockers (p  0.001) Beta-blockers (p 
xclusion of beta-blockers Exclusion of beta-blo
Rest level of both peptides (p  0.001) Rest level of both p
Increase in heart rate (p  0.007) Increase in heart ra
Maximal work load at exercise (p  0.020) Diuretics (p  0.00
Diuretics (p  0.021) Maximal work load
Maximal heart rate
bbreviations as in Tables 1 and 2.eptide storage is most important in patients with the wighest blood levels of NPs at rest. Therefore, it is also in
hese patients that exercise is expected to trigger the highest
eptide release from storage granules.
On multivariate analysis, the sole best independent pre-
ictors of NP concentrations at rest were aging and the
xtent of scarred LV area. This age dependence had already
een established (19,20), but no previous study has given
vidence of the dramatic influence of the extent of scarred
yocardium, as determined by myocardial SPECT. The
ationale of this observation is that, in patients with chronic
AD: 1) scarred territories are known to secrete high
mounts of BNP (21); and 2) the presence of large scarred
reas is a main cause of chronic cardiac overload, which is a
trong determinant of the increase in the rest concentrations
f NPs (1,2,18,22).
ombined influences of HR and beta-blockers. The
xercise increase in NP concentration was related to the
ncrease in HR at exercise. Previous studies performed
uring spontaneous tachycardia or ventricular pacing have
lready provided evidence that a prompt rise in HR was a
otent trigger of the acute release of BNP and especially of
hat of ANP (23,24). However, the present study shows that
his impact of HR is not the same when patients are treated
ith beta-blockers. As illustrated in Figure 3, for a given
ange of exercise increase in HR, the patients on beta-
lockers had much higher exercise increases in NP concen-
rations. The main consequence was that, during exercise,
he patients on beta-blockers reached higher blood levels of
Ps, despite lower increases in HR.
The difference in the exercise increase in NPs, which was
bserved between patients with and without beta-blockers,
ercise Increase in the Plasma Concentration of
BNP
All variables included
es (p  0.001) Rest level of BNP (p  0.001)
 0.001) Increase in rate–pressure product (p  0.001)
1) Beta-blockers (p  0.001)
LVEF (p  0.014)
es Exclusion of peptide dosages
 0.001) Extent of scarred area (p  0.001)
1) Increase in rate–pressure product (p  0.001)
Beta-blockers (p  0.013)
Age (p  0.016)
art rate Exclusion of increase in rate–pressure product
es (p  0.001) Rest level of BNP (p  0.001)
product (p  0.001) Maximal rate–pressure product (p  0.001)
7) Beta-blockers (p  0.001)
LVEF (p  0.010)
Exclusion of beta-blockers
es (p  0.001) Rest level of BNP (p  0.001)
 0.001) Increase in rate–pressure product (p  0.001)
LVEF (p  0.010)
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Cardiac NPs and Beta-Blockers February 4, 2004:353–9f plasma levels reported to induce a clear decrease in
ardiac load during the intravenous infusion of BNP or
NP (7,25–28). However, this difference was much lower
n patients with a low level of NPs at rest and therefore for
hom the physiologic impact of beta-blockers is more
ebatable. Nevertheless, it is likely that the enhanced release
f NPs might be an additional mechanism by which
eta-blockers lower cardiac work during stress, at least in
atients with diseased hearts and a high level of NPs at rest.
echanism of impact of beta-blockers. Beta-blockers
ave been shown to enhance the resting plasma levels of
Ps in patients with hypertension (29) and in those with
hronic heart failure (30). Up to now, however, no study has
nalyzed the effect of these drugs on the exercise secretion of
Ps. Exercising under beta-blockers leads to an increase
ardiac preload, as evidenced by larger LV cavities at end
iastole (31,32); thus, it may be wondered whether this also
eads to an increase in wall tension or pressure high enough
o trigger enhanced peptide release.
igure 2. Evolution of the plasma venous concentrations of natriuretic
eptides at rest, maximal exercise, and 20-min recovery, as well as the
xercise increase and post-exercise decrease in natriuretic peptide concen-
ration, for patients stratified according to the presence (black bars) or
bsence (white bars) of either beta-blocker treatment (upper half; n 
5/n  49) or a significant left ventricular scarred area on thallium-201
ingle-photon emission computed tomography (lower half; n  47/n 
7). The hatched portion of each bar represents the part related to the
trial natriuretic peptide concentration and the open portion of each bar
epresents the brain natriuretic peptide. *p  0.05.However, experimental studies have also shown that the pcute secretion of ANP was decreased by beta-agonists and
nhanced by alpha-agonists, even in the absence of any
emodynamic changes (studies on cultured myocytes [33]
r with selective intracoronary injection of agonists [34]).
hese experimental findings indicate direct but opposite
ffects of alpha- and beta-stimulation, which could explain
ur observations. First, alpha-stimulation enhances the
cute secretion of NPs, but in patients on beta-blockers, this
ay not be counterbalanced by the opposite effect of
eta-stimulation. Second, this unbalance between alpha-
nd beta-stimulation is likely to be exacerbated during the
ympathetic stimulation associated with exercise, thereby
xplaining our observation that beta-blockers had a clear
mpact on exercise release but not on rest concentration of
Ps.
Further studies are required to clarify the underlying
hysiologic mechanism. In addition, a limitation is that this
s only an observational study. Thus, further studies are
equired where the exercise release of NPs could be com-
ared between before and after the referral to beta-blockers.
p to now, such studies have never been conducted in
igure 3. Exercise increase in the total plasma venous concentrations of
atriuretic peptides, as determined by the difference between exercise and
est values (top), or as percentages of the baseline resting values (bottom)
or patients stratified into two groups according to the exercise increase in
eart rate ( or 51 beats/min) and into two subgroups as a function of
he presence (black bars) or absence (white bars) of beta-blocker treat-
ent. The hatched portion of each bar represents the part related to the
trial natriuretic peptide concentration and the open portion of each bar
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February 4, 2004:353–9 Cardiac NPs and Beta-BlockersNevertheless, this study shows that patients with chronic
AD exhibit higher exercise release of both BNP and ANP
hen their daily-life treatment includes beta-blockers. This
nhanced secretion of potent vasodilating and natriuretic
gents might constitute an additional and original mecha-
ism of these drugs for further protecting diseased hearts
gainst stress.
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